(4,5-dihydro-1H-imidazol-2-yl)-isobutyl-amine | 79013-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: (4,5-dihydro-1H-imidazol-2-yl)-isobutyl-amine
• 英文别名: (4,5-Dihydro-1H-imidazol-2-yl)-isobutyl-amin；2-Isobutylamino-Δ²-imidazolin；N-(2-methylpropyl)-4,5-dihydro-1H-imidazol-2-amine
• CAS: 79013-28-8
• 化学式: C₇H₁₅N₃
• 分子量: 141.216
• InChiKey: AZYNCNUYDQDFHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  36.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4,5-dihydro-1H-imidazol-2-yl)-isobutyl-amine 在 palladium on activated charcoal 氢气 、 sodium ethanolate 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 N-[7-Amino-2,3,5,8-tetrahydro-8-(2-methylpropyl)-5-oxoimidazo[1,2-a]pyrimidin-6-yl]formamide
  参考文献：
  名称：

  Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones

  摘要：

  The synthesis of a series of substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones is described. Several members of the series exhibit enhanced antiallergic and bronchodilator activity and reduced side effects as compared to theophylline. Structure-activity relationships and metabolic considerations are discussed for the series. Analogues substituted with a 4-(4-chlorobenzyl) moiety, such as 33 and 40, shown an optimal balance of antiallergic and bronchodilator activity and are of particular interest. Compound 33 is significantly more potent than theophylline against both metacholine- and antigen-induced bronchospasms, does not affect spontaneous motor activity, and shows minimal cardiovascular effects in the rat.

  DOI：

  10.1021/jm00185a008
• 作为产物：
  描述：

  异丁胺 、 2-甲硫基-2-咪唑啉 以 乙醇 为溶剂， 反应 2.0h， 生成 (4,5-dihydro-1H-imidazol-2-yl)-isobutyl-amine
  参考文献：
  名称：

  Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones

  摘要：

  The synthesis of a series of substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones is described. Several members of the series exhibit enhanced antiallergic and bronchodilator activity and reduced side effects as compared to theophylline. Structure-activity relationships and metabolic considerations are discussed for the series. Analogues substituted with a 4-(4-chlorobenzyl) moiety, such as 33 and 40, shown an optimal balance of antiallergic and bronchodilator activity and are of particular interest. Compound 33 is significantly more potent than theophylline against both metacholine- and antigen-induced bronchospasms, does not affect spontaneous motor activity, and shows minimal cardiovascular effects in the rat.

  DOI：

  10.1021/jm00185a008

文献信息

• BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20160009637A1

  公开（公告）日：2016-01-14

  The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其具有位于脂质基团（例如，疏水链）的中部或远端部位的一个或多个可生物降解的基团。这些阳离子脂质可以被纳入脂质颗粒中，用于传递活性剂，例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质颗粒。脂质颗粒还可以进一步包含治疗剂，如核酸。
• ADAM10 and its Uses Related to Infection
  申请人：Rubin Donald H.

  公开号：US20090220514A1

  公开（公告）日：2009-09-03

  The present invention relates to a protein, ADAM10, ADAM10 nucleic acid sequences and ADAM10 proteins encoded by these sequences that are involved in infection by one or more pathogen such as a virus, a parasite, a bacteria or a fungus or are otherwise associated with the life cycle of a pathogen.

  本发明涉及一种蛋白质ADAM10，ADAM10核酸序列和由这些序列编码的ADAM10蛋白质，它们参与感染一种或多种病原体，例如病毒、寄生虫、细菌或真菌，或与病原体的生命周期有关。
• Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20150005363A1

  公开（公告）日：2015-01-01

  The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种具有公式（I）的阳离子脂质，其中在脂质部分（例如，疏水链）中具有一个或多个可生物降解的基团。这些阳离子脂质可以被纳入到脂质粒中，以传递活性剂，例如核酸。本发明还涉及包括中性脂质、能够减少聚集的脂质、本发明中的阳离子脂质以及可选的固醇的脂质粒。该脂质粒还可以包括治疗剂，例如核酸。
• CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20140350113A1

  公开（公告）日：2014-11-27

  Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.

  本文描述了CD4的小分子模拟物，它们进入Phe43腔并靶向HIV-1包膜蛋白gp120的Asp368。本文还描述了使用这些化合物抑制HIV感染的传播或进展的方法。这些化合物表现出比已知抗病毒药物NBD-556更强的抗病毒效力，对B和C类病毒具有100％的广度。重要的是，与NBD-556相比，这些化合物不会激活CD4阴性，CCR5阳性细胞的HIV感染。
• Human adam-10 inhibitors
  申请人：Brown S. David

  公开号：US20090143386A1

  公开（公告）日：2009-06-04

  The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chlorides and ADAM-10 modulators therefrom.

  本发明提供了用于抑制ADAM-10蛋白的化合物。这些化合物在体外研究ADAM-10（及其抑制）在生物过程中的作用方面非常有用。本发明还包括与一种或多种本发明的ADAM-10抑制剂结合的药学上可接受的载体组成的制药组合物。这样的组合物在治疗癌症、关节炎和与血管生成相关的疾病方面非常有用。相应地，本发明还包括治疗癌症、关节炎和与血管生成相关的疾病的方法，其中ADAM-10发挥关键作用。本发明还提供制备双芳基醚磺酰氯和ADAM-10调节剂的方法。